Sign In
Buy IOVA
$4.07
-0.620 (-13.22%)
At Close: Jul 31, 2026
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of “Hold” by Brokerages
02:27am, Saturday, 28'th Mar 2026
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) have been assigned an average recommendation of "Hold" from the twelve brokerages that are presently covering the firm, Marketb
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 26'th Mar 2026
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 20'th Mar 2026
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
03:25pm, Thursday, 12'th Mar 2026
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
12:42pm, Wednesday, 11'th Mar 2026
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
What's Going On With Iovance Biotherapeutics Stock On Friday?
01:06pm, Friday, 06'th Mar 2026
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week High After Analyst Upgrade
01:52am, Friday, 06'th Mar 2026
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) reached a new 52-week high during trading on Thursday after UBS Group raised their price target on the stock from $2.00 to $4.0
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
05:27pm, Thursday, 05'th Mar 2026
Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky.
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
12:17pm, Wednesday, 04'th Mar 2026
Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a p
Iovance Biotherapeutics to Present at Upcoming Conferences
08:00am, Thursday, 26'th Feb 2026
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
01:33pm, Wednesday, 25'th Feb 2026
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
12:06pm, Wednesday, 25'th Feb 2026
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
03:43pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B pe
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
02:14pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarc
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
12:57pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
